Knudtson et al. concluded: ‘‘physicians can now inform patients that there is no scientific evidence to support the claim that $4000 per year for chelation therapy with EDTA is money well spent.’’ The fact that controversial chelation therapy is still practiced indicates that we do not have treatment that provides satisfactory beneficial effects for the majority of patients treated for obstructive coronary artery disease and that more research is required. The idea of chelation should not be abandoned. EDTA has had its day but perhaps other molecules that can dissolve plaques of atheroma should be sought.